INTRODUCTION
Tissue extravasation with ischemia and dermal necrosis has been associated with the use of dopamine intravenous infusions. This complication has been reported with the administration of dopamine (Dopamine, AstraZeneca, London, UK) at dosages over 5 g/kg per minute. 1 -12 However, in English literature, only five such cases in the adult literature have been reported in which dopamine was infusing at a dosage of less than 5 g/kg per minute. These patients suffered ischemia and gangrene in two cases 13, 14 and extravasation with tissue injury in three cases. 15, 16 In the neonatal population, there have only been two case reports of high-dose dopamine extravasation and ischemia, reversed with nitroglycerin 12 in one case and phentolamine (Regitine, NOVARTIS, Basel, Switzerland) in the other case. 10 In both cases, the dopamine infusion was 10 g/kg per minute. To our knowledge, we report the first case of peripheral tissue ischemia in a neonate associated with extravasation of very-low-dose dopamine infusion (3 g/kg per minute). This infant was successfully treated with phentolamine.
CASE REPORT
A full-term male infant was vaginally delivered at a community hospital 1 hour after spontaneous rupture of membranes. The pregnancy and labor were uncomplicated and the infant weighed 3340 g. The infant was admitted to the normal newborn nursery, but at about 7 hours of life, respiratory distress with increased work of breathing was noted. A sepsis work-up was done, including a lumbar puncture, and the infant was started on intravenous antibiotics. A complete blood count revealed a WBC of 34,000/mm 3 with 80% lymphocytes, 13% neutrophils, and 2% bands. He required supplemental oxygen of 40% to 50% and was transferred to University Hospital Neonatal Intensive Care Unit for further management. Upon arrival, he was noted to have delayed capillary refill ( >3 seconds) and a low blood pressure (30/10 mm Hg). He was afebrile and his heart rate was 125 beats/min. A fluid bolus of normal saline (10 ml/kg) was administered without significant response. Low-dose dopamine was started at 3 g/kg per minute in a peripheral vein in the left lower extremity. After just 3 hours of dopamine infusion, the left leg was noted to be swollen, erythematous, infiltrated, and with surrounding extravasation (Figure 1 ). The dopamine infusion was discontinued and the angiocatheter was removed. A provisional diagnosis of dopamine-associated dermal ischemia was made. Although the overall perfusion of the infant had significantly improved and the blood pressure was maintained without the dopamine, the area of extravasation in the left lower calf was affected for some 2 hours after the intravenous infusion was removed. It was edematous, cool, pale, and blanching. Within the next few hours, the area of involvement extended to the surrounding skin with linear, serpiginous, pale gray, demarcated zone in the center and peripheral area of erythema extending from the medial aspect of the ankle and malleolus to the medial aspect of the knee (Figure 1 ). The skin was grossly intact and the capillary refill remained delayed by 3 to 4 seconds. The affected area measured approximately 7Â1.75 cm 2 . Due to the rapidity with which these changes had progressed and dopamine-associated dermal necrosis was anticipated, phentolamine was administered subcutaneously in a total dose of 3.5 ml (approximately 1 ml/ kg dose) encircling the infiltrated site at four different entry points in the skin. A remarkable and instantaneous improvement in color and perfusion was noted within 15 to 30 seconds of Skin ischemia, necrosis, and gangrene are uncommon but known complications of dopamine extravasation. In most cases, these complications are associated with the use of high -dosage dopamine infusion. Subcutaneous phentolamine has been used as a therapeutic agent for these complications. However, this is the report of the first neonatal case report in the English literature of prompt reversal of imminent dermal ischemia and necrosis associated with low -dose dopamine infusion using subcutaneous phentolamine. 
Clinical Perinatal/Neonatal Case Presentation
phentolamine administration adjacent to the infiltrated site.
Within the next few hours, there was complete resolution of the discoloration. The infant's blood pressure and other vital signs remained stable during and after the phentolamine treatment.
No additional phentolamine was given. Oxygen requirement resolved within 24 hours and the antibiotics were discontinued after the blood culture was read as negative. The patient had complete resolution of this ischemic event and was discharged at 4 days of life without adverse outcome to the extremity at 3 months follow up.
DISCUSSION
Dopamine is a naturally occurring endogenous catecholamine and is a precursor of norepinephrine and epinephrine. It has been widely used in the pediatric and neonatal population for the treatment of hypotension and oliguria, often as a first-line treatment following fluid resuscitation. While it is commonly used in a peripheral vein with few reported side effects, it is well known to cause local vasoocclusive effects for some length of the vein (dopamine streak). This effect is transient in nature and subsides after the infusion is stopped. Dose-dependent cardiovascular, renal, and endocrine effects of dopamine help to combat the manifestations of shock syndromes presumably by selective activation of various receptors. At infusions over 10 g/kg per minute, dopamine increases systemic vascular resistance and mean arterial pressure by predominant alpha-adrenergic receptor activation. At doses of 3 to 10 g/kg per minute, dopamine increases cardiac contractility and cardiac output primarily as a result of beta-adrenergic receptor activation. Occasionally, dopamine is used in even lower doses of <3 g/kg per minute, a dose thought to increase the renal perfusion through the activation of dopamine D1 receptors located in the renal vasculature with no appreciable betaadrenergic stimulation.
Most of the adverse effects reported with dopamine have occurred after using the high-dosage infusion treatment. This has led to a common misperception that low-dosage dopamine infusion is benign. 17 In this case report, we demonstrate that dopamine extravasation, even at low-dosage infusions, can cause severe vasoconstriction and tissue ischemia probably by achieving high local concentrations. The mechanism of skin necrosis still remains unclear. Moreover, a rat model of dopamine-associated tissue ischemia was related to the duration of the infiltration and extravasation rather than the volume or concentration of the dopamine.
Phentolamine has been recognized as a therapeutic agent for the prevention of dermal necrosis and sloughing caused by extravasation of vasoconstrictive agents, including dopamine. Early recognition and prompt treatment of the affected area with an alpha-receptor antagonist like phentolamine may prevent permanent injury and the need for skin grafting. Phentolamine is an alpha-adrenergic receptor blocking agent that produces peripheral vasodilatation, thereby reversing ischemia produced by vasopressor infiltration. Subcutaneous injection of a 1-mg/ml solution of phentolamine has been recommended as the dosage in adults. 18 In animal studies, 19 doses as low as 0.5 mg/kg have been reported to be equally effective in reversing the ischemic effects of dopamine extravasation. The effect of phentolamine is seen almost instantly and the dose may be repeated if necessary. The biological half-life of subcutaneous phentolamine administration is reported to be less than 20 minutes. 18 Patients need to be closely monitored after phentolamine since the most nefarious side effect of a very large dose is hypotension.
CONCLUSION
We report a rare case of low-dose dopamine administration associated with dermal ischemia reversed by subcutaneous phentolamine in a neonate. Since severe vasoconstriction and dermal injury can occur in cases of extravasation of even lowdose dopamine, central venous catheter infusion should be the preferred route for all dopamine administrations. When this is not possible, peripheral vein infusion sites need to be checked frequently for signs of extravasation even with low-dose infusion. The same vigilant precautions need to be followed whenever dopamine is being infused.
